Home > Oncology > New class of cancer drugs down, not out, after Roche trial setback – analysts

New class of cancer drugs down, not out, after Roche trial setback – analysts

Reuters - 11/05/2022 - The fresh blow to Roche's hopes in a closely watched class of cancer immunotherapies cast a long shadow across the crowded field on Wednesday, but the latest setback is not the end of the road for these oncology treatments, analysts say. Roche said an interim analysis of an ongoing clinical trial showed that its experimental drug, tiragolumab, failed to meaningfully slow disease progression in newly diagnosed patients with advanced non-small-cell lung cancer (NSCLC) in combination with its approved PD-L1 immunotherapy Tecentriq, versus Tecentriq alone. The study will continue to evaluate whether the combination helps patients live longer, the gold standard for cancer treatments. The news comes after the Swiss drugmaker disclosed in March tiragolumab had failed to slow progression of a rarer, more aggressive form of lung cancer. Analysts had assigned a higher likelihood of success to the NSCLC trial, since it included patients wit...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on